Tempus AI to Acquire Personalis in $1.5B Deal — Needham Flags a Premium Well Above Peers
Tempus AI, Inc. (NASDAQ: TEM) has agreed to buy cancer-test maker Personalis, Inc. (NASDAQ: PSNL) in a $1.5 billion deal that Needham says carries a premium well above comparable transactions.
The Deal Terms
Under the agreement announced Monday, Tempus AI will acquire all Personalis shares it doesn’t already own for $16.25 apiece, using a floating exchange ratio capped at 0.3356 Tempus shares. That price marks a 6% premium to Friday’s close and a 28% premium to the 30-day average. Notably, Tempus retains the flexibility to pay up to half of the consideration in cash.
Why Needham Calls the Premium Steep — but Justified
At $16.25 per share, the deal values Personalis at a forward enterprise value-to-sales multiple of 15.5 — well above the median for its small- and mid-cap growth peers, according to a Needham note. Even so, the firm’s analysts argue the premium makes sense. They point to strong test-volume growth in NeXT Personal, several Medicare reimbursement wins across breast cancer, lung cancer, and immunotherapy monitoring, and a large addressable market in minimal residual disease (MRD) testing.
The Strategic Rationale
For Tempus, the acquisition deepens its push into MRD, letting it support cancer patients from diagnosis through long-term monitoring. Personalis’ NeXT Personal test relies on MRD technology, and demand for that kind of ongoing surveillance keeps climbing — roughly 2.1 million Americans are expected to receive a cancer diagnosis this year alone.
Tempus AI CEO Eric Lefkofsky framed the move as a natural extension of an existing partnership. “Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure,” he said, adding that building clinical adoption and reimbursement momentum makes the acquisition “particularly exciting.” Personalis CEO Chris Hall echoed the optimism, saying Tempus’ offer “provides the most value to our shareholders and the fastest path to bringing Personalis’ industry-leading tests to patients.”
Market Reaction and Analyst Call
Investors, however, reacted cautiously. Tempus AI shares fell 6.5% in Monday afternoon trading, while Personalis slumped 13%. Meanwhile, Needham downgraded Personalis to hold from buy, reasoning that competing bids and antitrust complications both look unlikely — leaving little additional upside from here.
What Comes Next
Looking ahead, the companies expect the transaction to close in late 2026 or early 2027, pending Personalis shareholder approval and regulatory clearance. The deal also extends Tempus’ aggressive acquisition streak; over the past year, the company has already scooped up genetic-testing firm Ambry Genetics, research platform Deep 6 AI, and digital-pathology developer Paige.
